Oncology Letters · 2015 · 15 citations · 22 references
MedicineOncologyPharmacologyChemotherapyEpigeneticsMolecular OncologyCancer EpigeneticsCancer Stem CellsDna MethylationEpigenetic Alterations In CancerMalignant NeoplasmsTesticular CancerCancer Dna Methylation SignaturesDna Methylation PatternsEpigenetic Alterations In CarcinogenesisEpigenetic CarcinogenesisEpigenetic Drug ResistanceStem Cell Differentiation Status AssessmentStemness RegulationTesticular Cancer Chemotherapy
Dimethyl sulfoxide (DMSO) is an amphipathic molecule that is used as a solvent in biological studies and as a vehicle for drug therapy. The present study was designed to evaluate the potential effects of DMSO as a solvent in the treatment of testicular embryonal carcinomas (ECs). DMSO was applied to two human EC cell lines (NEC8 and NEC14), with the treated cells evaluated in relation to cisplatin (CDDP) resistance, differentiation (using Vimentin, Fibronectin, TRA-1-60, and SSEA-1 and -3 as markers) and stemness (denoted by expression of SOX2 and OCT3/4). Furthermore, DNA methyltransferase (DNMT-1, -3A and -3L) expression and methylation status were analyzed. DMSO induced resistance to CDDP, aberrant differentiation and reduction of stemness-related markers in each of the EC cell lines. The expression levels of DNMT-3L and -3A were reduced in response to DMSO, while this treatment also affected DNA methylation. The data demonstrated that DMSO perturbed differentiation, reduced stemness and induced resistance to CDDP in human EC cells. Therefore, DMSO could reduce drug efficacy against EC cells and its use should be carefully managed in the clinical application of chemotherapy.
22
High sensitivity mapping of methylated cytosines
J.CIark Susan, Cheryl Paul, Marianne Frommer · Nucleic Acids Research · 1994 · 1.9K citations · Full text
POSSIBLE CARCINOMA-IN-SITU OF THE TESTIS
NielsE. Skakkebæk · The Lancet · 1972 · 746 citations